Johnson & Johnson (JNJ) Stock
Global healthcare giant with medicines, devices and consumer goods. Here's the price, business snapshot, and what's worth knowing about Johnson & Johnson in October 2026.
Johnson & Johnson (JNJ) is a large, diversified healthcare company operating across pharmaceuticals, medical devices and consumer health products. With a market capitalisation of about $462.11 billion, it mixes steady cash-generative consumer brands with higher-growth prescription medicines and device franchises. Investors often watch J&J for its scale, research and development pipeline, global reach and long record of dividend payments, but the company also faces patent expiries, regulatory scrutiny, litigation risk and competition that can affect earnings. Financial performance may be influenced by new product approvals, M&A activity and macroeconomic conditions. This summary is general, educational information only and not personal advice — investing carries risk and past performance is not a reliable guide to future results. Consider consulting a financial professional about suitability for your circumstances.
Why It’s Moving
JNJ Pipeline Momentum: Strong Clinical Data and Regulatory Wins Offset Valuation Concerns
- New Phase 1b/2 data for subcutaneous RYBREVANT (amivantamab) demonstrated a 77% overall response rate in first-line treatment for advanced head and neck cancer, supporting the ongoing pivotal Phase 3 study.
- Experimental drug JNJ-6143 showed promising early-stage results in advanced prostate cancer, with 75% of patients achieving complete or partial tumor responses and significant PSA reductions.
- The UK medicines regulator approved J&J's daily oral pill for moderate-to-severe plaque psoriasis, expanding its commercial footprint in dermatology alongside strong dividend history.
JNJ Pipeline Momentum: Strong Clinical Data and Regulatory Wins Offset Valuation Concerns
- New Phase 1b/2 data for subcutaneous RYBREVANT (amivantamab) demonstrated a 77% overall response rate in first-line treatment for advanced head and neck cancer, supporting the ongoing pivotal Phase 3 study.
- Experimental drug JNJ-6143 showed promising early-stage results in advanced prostate cancer, with 75% of patients achieving complete or partial tumor responses and significant PSA reductions.
- The UK medicines regulator approved J&J's daily oral pill for moderate-to-severe plaque psoriasis, expanding its commercial footprint in dermatology alongside strong dividend history.
Sixth Month Growth Performance
When is the next earnings date for Johnson & Johnson (JNJ)?
Johnson & Johnson has not yet announced a confirmed date for its next earnings report. Based on the company's historical pattern of reporting approximately three months after the previous quarter, the upcoming release is expected in January 2027. This report will cover the fourth quarter and full-year results for fiscal 2026. Investors should monitor official communications for the precise scheduling details as they become available.
Stock Performance Snapshot
Analyst Rating
Analysts advise buying Johnson & Johnson's stock, expecting it to rise towards $225.92.
Financial Health
Johnson & Johnson shows strong revenue, cash flow, and profitability, demonstrating solid financial performance.
Dividend
Johnson & Johnson's dividend yield of 1.96% is lower than many investors might prefer for dividend income. If you invested $1000 you would be paid $19.68 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Diversified revenue base
Pharmaceuticals, devices and consumer products spread revenue sources, which can smooth cycles — though divisions face different risks and growth prospects.
R&D and pipeline
A strong research pipeline can drive future growth if approvals succeed, but clinical setbacks or regulatory delays can weigh on returns.
Global footprint
Sales across many markets provide scale and resilience, yet global regulation, litigation and supply-chain risks can affect performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
